跳至主要内容
临床试验/NCT01126879
NCT01126879终止2 期

Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells

Northwestern University2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年2月3日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
终止
入组人数
12
试验地点
2
主要终点
Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs

研究概览

简要总结

RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.

详细描述

PRIMARY OBJECTIVES:

I. Determine whether genistein treatment will decrease the number of circulating prostate cells (CPCs) in the peripheral blood as measured by qRT-PCR for PSA performed on RNA extracted from peripheral blood mononuclear cells (PBMNCs).

SECONDARY OBJECTIVES:

I. Determine the natural history of circulating prostate cells (CPCs) in a cohort of subjects prior to and post radical prostatectomy.

II. Compare the measurement of PSA between three separate methods: in CPCs by qRT-PCR, in serum by the standard clinical chemistry assay (i.e., ELISA), and in plasma and serum by the nano-PSA assay.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Arm I

Experimental

Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.

干预措施: genistein (Dietary Supplement)

Arm I

Experimental

Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.

干预措施: therapeutic conventional surgery (Procedure)

Arm II

Placebo Comparator

Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.

干预措施: placebo (Other)

Arm II

Placebo Comparator

Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.

干预措施: therapeutic conventional surgery (Procedure)

结局指标

主要结局

Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs

时间窗: At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery

Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.

次要结局

  • Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue(At baseline and at time of surgery)
  • Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy(At baseline, 1 and 12 months after surgery)
  • Measurement of PSA in Serum and Plasma by Nanotechnology(At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Genistein in Treating Patients With Prostate Cancer | 临床试验